Abstract
The APJ is a class A, rhodopsin-like G protein-coupled receptor (GPCR) with high sequence similarity to the angiotensin receptor AT1. APJ has been shown to be widely expressed in humans tissues, including the central nervous system, cardiovascular system, adipocytes and others. APJ plays an important role in the occurrence and development of cardiovascular and metabolic diseases including atherosclerosis (AS), coronary heart disease (CAD), heart failure(HF), pulmonary arterial hypertension (PAH), myocardial hypertrophy and atrial fibrillation, especially hypertension. Previous researchers found that apelin/APJ could induce vasodilation and then reduce blood pressure. Despite APJ is closely associated with many diseases, there are no drugs that can activate or inhibit APJ directly. In the current review, we have summarized recently reported peptides, small molecule agonists and antagonists targeting APJ. Given the role of apelin/APJ in hypertension and other cardiovascular diseases, we believe that the peptides and compounds based on APJ will be developed for treatment of these diseases.
Keywords: Agonists, antagonists, anti-hypertension, apelin, APJ, novel compounds, target.
Current Drug Targets
Title:Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Volume: 16 Issue: 2
Author(s): Jiangang Cao, Hening Li and Linxi Chen
Affiliation:
Keywords: Agonists, antagonists, anti-hypertension, apelin, APJ, novel compounds, target.
Abstract: The APJ is a class A, rhodopsin-like G protein-coupled receptor (GPCR) with high sequence similarity to the angiotensin receptor AT1. APJ has been shown to be widely expressed in humans tissues, including the central nervous system, cardiovascular system, adipocytes and others. APJ plays an important role in the occurrence and development of cardiovascular and metabolic diseases including atherosclerosis (AS), coronary heart disease (CAD), heart failure(HF), pulmonary arterial hypertension (PAH), myocardial hypertrophy and atrial fibrillation, especially hypertension. Previous researchers found that apelin/APJ could induce vasodilation and then reduce blood pressure. Despite APJ is closely associated with many diseases, there are no drugs that can activate or inhibit APJ directly. In the current review, we have summarized recently reported peptides, small molecule agonists and antagonists targeting APJ. Given the role of apelin/APJ in hypertension and other cardiovascular diseases, we believe that the peptides and compounds based on APJ will be developed for treatment of these diseases.
Export Options
About this article
Cite this article as:
Cao Jiangang, Li Hening and Chen Linxi, Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450115666141128120053
DOI https://dx.doi.org/10.2174/1389450115666141128120053 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design Sex-Related Differences in QTc Effects Potential of Drugs
Reviews on Recent Clinical Trials Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Current Signal Transduction Therapy Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Preface: MicroRNA as Disease Biomarkers
MicroRNA Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews Podocytes as a Target of Insulin
Current Diabetes Reviews Flavonoids and Chagas' Disease: The Story So Far!
Current Topics in Medicinal Chemistry Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research The Concept of Depression as a Dysfunction of the Immune System
Current Immunology Reviews (Discontinued) Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design